Dyne Therapeutics 40% Rally Faces Fund Selloff Questions
A dramatic 40% jump for Dyne Therapeutics has investors watching closely as a biotech-focused fund disclosed a sizabl...
A clear look at the stablecoins that outperformed peers this year, with insights into drivers and risk considerations for future allocations.
26,211 articlesA dramatic 40% jump for Dyne Therapeutics has investors watching closely as a biotech-focused fund disclosed a sizabl...
When Cerebras surged 68% on its first trading day, investors sat up and took notice. This piece breaks down what that...
Dell stock is on a rapid uptrend as profits beat expectations. This guide breaks down whether the rally can continue ...
Rivian's R2 rollout marks a new chapter for the EV maker. This guide breaks down whether the stock deserves a place i...
As AI reshapes manufacturing and logistics, the ROBO ETF is gaining attention for its diversified approach to robotic...
A comeback that ends in minutes isn't just sports news—it’s a blueprint for financial planning. Learn how to shield y...
A reserves-and-resources update put Coeur Mining back in focus, with millions of ounces of gold on the books and a pr...
Kontoor Brands stock popped as the company posted a better-than-expected quarter and issued a brighter path for 2026....
As mortgage rates shift and originations evolve, loandepot (LDI) 2025 earnings will hinge on rate flow, loan mix, and...
Planet Labs stock popped today after a standout quarter and optimism about a path to profitability. This article brea...
Upstart’s growth engine faces higher costs that squeeze margins, triggering a drop in price even when revenue beats. ...
Artificial intelligence is reshaping how companies operate and profit. This article breaks down how AI is fueling ear...